A Multicenter Open LableDose Escalat Tion and Dose Expansion Clinical Study to Evaluate the Safety, Tolerance and Ini Itial Effectiveness of WTX212A Injection in Patients with Unresectable or Metastatic Advanced Solid Tumors
Latest Information Update: 21 Jan 2025
At a glance
- Drugs WTX 212 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 16 Jan 2025 Planned End Date changed from 30 May 2025 to 30 Aug 2026.
- 16 Jan 2025 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2026.
- 20 May 2024 New trial record